261 related articles for article (PubMed ID: 9633022)
1. Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.
Funahashi H; Tanaka Y; Imai T; Wada M; Tsukamura K; Hayakawa Y; Matsuura N; Kikumori T; Oiwa M; Tominaga Y; Takagi H
J Endocrinol Invest; 1998 Jan; 21(1):43-7. PubMed ID: 9633022
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
Brown AJ; Ritter CR; Finch JL; Morrissey J; Martin KJ; Murayama E; Nishii Y; Slatopolsky E
J Clin Invest; 1989 Sep; 84(3):728-32. PubMed ID: 2760211
[TBL] [Abstract][Full Text] [Related]
4. Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH)2D3.
Finch JL; Brown AJ; Mori T; Nishii Y; Slatopolsky E
J Bone Miner Res; 1992 Jul; 7(7):835-9. PubMed ID: 1642151
[TBL] [Abstract][Full Text] [Related]
5. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism.
Finch JL; Brown AJ; Kubodera N; Nishii Y; Slatopolsky E
Kidney Int; 1993 Mar; 43(3):561-6. PubMed ID: 8455354
[TBL] [Abstract][Full Text] [Related]
7. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
Takahashi F; Furuichi T; Yorozu K; Kawata S; Kitamura H; Kubodera N; Slatopolsky E
Nephrol Dial Transplant; 2002; 17 Suppl 10():46-52. PubMed ID: 12386269
[TBL] [Abstract][Full Text] [Related]
8. The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands.
Brown AJ; Zhong M; Finch J; Ritter C; Slatopolsky E
Endocrinology; 1995 Apr; 136(4):1419-25. PubMed ID: 7895652
[TBL] [Abstract][Full Text] [Related]
9. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
Tsukamoto Y; Nomura M; Takahashi Y; Takagi Y; Yoshida A; Nagaoka T; Togashi K; Kikawada R; Marumo F
Nephron; 1991; 57(1):23-8. PubMed ID: 2046811
[TBL] [Abstract][Full Text] [Related]
10. On the mechanisms for the selective action of vitamin D analogs.
Dusso AS; Negrea L; Gunawardhana S; Lopez-Hilker S; Finch J; Mori T; Nishii Y; Slatopolsky E; Brown AJ
Endocrinology; 1991 Apr; 128(4):1687-92. PubMed ID: 2004595
[TBL] [Abstract][Full Text] [Related]
11. In vivo regulation of chromogranin A messenger ribonucleic acid in the parathyroid by 1,25-dihydroxyvitamin D: studies in normal rats and in chronic renal insufficiency.
Soliman E; Canaff L; Fox J; Hendy GN
Endocrinology; 1997 Jun; 138(6):2596-600. PubMed ID: 9165053
[TBL] [Abstract][Full Text] [Related]
12. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
Nishii Y; Abe J; Mori T; Brown AJ; Dusso AS; Finch J; Lopez-Hilker S; Morrissey J; Slatopolsky E
Contrib Nephrol; 1991; 91():123-8. PubMed ID: 1800003
[TBL] [Abstract][Full Text] [Related]
13. 1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture.
Cantley LK; Russell J; Lettieri D; Sherwood LM
Endocrinology; 1985 Nov; 117(5):2114-9. PubMed ID: 3840080
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
Tamura S; Ueki K; Mashimo K; Tsukada Y; Naitoh M; Abe Y; Kawai H; Tsuchida A; Wakamatsu R; Nojima Y
Clin Exp Nephrol; 2005 Sep; 9(3):238-43. PubMed ID: 16189633
[TBL] [Abstract][Full Text] [Related]
15. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
16. Regulation of parathyroid hormone synthesis in chronic renal failure in rats.
Fukagawa M; Kaname S; Igarashi T; Ogata E; Kurokawa K
Kidney Int; 1991 May; 39(5):874-81. PubMed ID: 2067203
[TBL] [Abstract][Full Text] [Related]
17. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.
Hirata M; Endo K; Katsumata K; Ichikawa F; Kubodera N; Fukagawa M
Nephrol Dial Transplant; 2002; 17 Suppl 10():41-5. PubMed ID: 12386268
[TBL] [Abstract][Full Text] [Related]
18. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus.
Yi H; Fukagawa M; Yamato H; Kumagai M; Watanabe T; Kurokawa K
Nephron; 1995; 70(2):242-8. PubMed ID: 7566311
[TBL] [Abstract][Full Text] [Related]
19. Adaptation of parathyroid function to intravenous 1,25-dihydroxyvitamin D3 or partial parathyroidectomy in normal dogs.
Cloutier M; Gagnon Y; Gascon-Barré M; Brossard JH; D'Amour P
J Endocrinol; 1997 Oct; 155(1):133-41. PubMed ID: 9390015
[TBL] [Abstract][Full Text] [Related]
20. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure.
Denda M; Finch J; Slatopolsky E
Am J Kidney Dis; 1996 Oct; 28(4):596-602. PubMed ID: 8840952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
